Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2

5 Apr 2022

Abstract excerpt

In the fight against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), monoclonal antibodies (mAbs) serve as key strategies for the rapid prevention and treatment of COVID-19. However, analysis to fully characterize functional SARS-CoV-2 mAbs is still needed. In this study, by interrogating 1,695 published or patented mAbs of human origin and validated SARS-CoV-2-binding potency, we found a highly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunodeficiency and Autoimmune Disorders
Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35380101
DOI: 10.1080/22221751.2022.2063074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2PMID 35380101Read ↗

Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patientsSemantic proximity Read ↗

Somatic evolution of a cross-reactive germline antibody that expands its breadth to neutralize new SARS-CoV-2 variantsSemantic proximity Read ↗

Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domainSemantic proximity Read ↗

Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including BQ and XBB lineagesSemantic proximity Read ↗

Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variantsSemantic proximity Read ↗

Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2Semantic proximity Read ↗

Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variantsSemantic proximity Read ↗

Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2Semantic proximity Read ↗

A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversificationSemantic proximity Read ↗

Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escapeSemantic proximity Read ↗

Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silicoSemantic proximity Read ↗

Structural determinants of IGHV1-69 public antibodies conferring resilience to SARS-CoV-2 antigenic escapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.